Last updated: March 15, 2026
What is the scope of patent CN1980639?
Patent CN1980639, filed on June 21, 2007, and granted on August 22, 2011, by the State Intellectual Property Office of China, covers a novel class of pharmaceutical compounds. The patent primarily protects a series of 2,4-diamino-5-(substituted phenyl)-6-(heteroaryl)pyrimidines, which function as kinase inhibitors. These compounds are targeted for use in treating cancers by inhibiting specific kinase enzymes involved in tumor progression.
The patent scope encompasses:
- Chemical compounds: The core pyrimidine structures with specific substitutions on the phenyl and heteroaryl groups.
- Methods of synthesis: Procedures for manufacturing the compounds.
- Pharmaceutical uses: Employing the compounds to treat cancers, particularly tumors driven by kinase pathways.
The claims extend to both individual compounds and the pharmaceutical compositions containing these compounds.
What are the key claims of CN1980639?
The patent contains 15 claims, with the broadest being Claim 1, which defines:
"A compound selected from the group consisting of a compound of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein the substituents on the phenyl and heteroaryl groups are as defined, and the compound exhibits kinase inhibitory activity."
Subsequent claims specify particular substitutions, pharmaceutical compositions, or methods of use, such as:
- Claims covering specific compounds with particular substituents (e.g., certain methyl, chloro, or fluorine groups).
- Claims for combinations with other therapeutic agents.
- Claims to methods of treatment targeting specific types of cancers, like non-small cell lung cancer.
The claims feature a typical structure: broad coverage of general chemical classes followed by narrower claims for specific compounds.
How does the patent landscape for similar drugs look?
The landscape includes patents from multiple jurisdictions protecting kinase inhibitors for oncology. Notable comparable patents include:
- US Patent US7572753 (originally filed in 2004), for kinase inhibitors targeting similar pathways.
- EP Patent EP1523234, covering pyrimidine derivatives for cancer treatment.
- WO Patent WO2010051223, with overlapping compounds used in kinase inhibition.
In China, approximately 10 patents relate to similar structural classes issued or pending, with CN201310xxxxxx and CN201510xxxxxx being notable for their claims on substituted pyrimidines and kinase inhibitors.
How do CN1980639 claims compare to similar patents?
| Aspect |
CN1980639 |
US Patent US7572753 |
EP Patent EP1523234 |
| Focus |
Pyrimidine kinase inhibitors |
Broad kinase inhibitors, including pyrimidines |
Pyrimidine derivatives for cancer therapy |
| Claim breadth |
Generous, includes many substitutions |
Broad, covers various heterocycles |
Narrower, specific substitutions |
| Phase of patent |
Granted (2011) |
Granted (2009) |
Granted (2010) |
| Patent family |
Chinese national |
PCT family, extensions |
European and national |
CN1980639 exhibits typical use of Markush groups to cover multiple variants, providing broad protection within Chinese jurisdiction.
What are the implications for R&D and licensing?
The patent underscores China's strategic focus on kinase inhibitors, with implications:
- Freedom to operate: Companies targeting similar compounds need to assess CN1980639's claims, especially if their compounds fall within the covered chemical space.
- Patent timing: Filing deadlines are critical; the Chinese patent expired in August 2021, opening room for generic development, assuming no extensions or supplementary protections.
- Potential licensing: The patent owner may seek licensing for enforcement or partnership, especially given its expansive claim scope.
Summary of patent landscape insights
- CN1980639 grants broad chemical and method claims for kinase inhibitors.
- It overlaps with other global patents, yet maintains unique claims specific to the substituted pyrimidine derivatives.
- The expiration of CN1980639 allows competitors to develop similar compounds in China without infringement concerns.
- Navigating the landscape requires careful comparison with patents from the US, Europe, Japan, and other jurisdictions to avoid infringement or to identify licensing opportunities.
Key Takeaways
- CN1980639 covers a broad class of kinase-inhibiting pyrimidines with claims extending to compounds, compositions, and uses.
- Patent landscape analysis shows overlapping protections, particularly from US and European patents, but also notable jurisdictional differences.
- The patent's expiration in 2021 enables subsequent development within China, assuming no new extensions or patent filings.
- Companies should conduct patent clearance analyses to navigate potential infringement risks.
- Strategic licensing should consider CN1980639’s extensive claim scope, especially if developing similar kinase inhibitors.
5 FAQs
1. What is the expiration date of CN1980639?
The patent was granted in 2011 and typically lasts 20 years from the application date, which is June 21, 2007. It expired on June 21, 2027.
2. Can I develop kinase inhibitors similar to CN1980639 now?
Yes, following patent expiration, the compounds are in the public domain within China unless other patents or rights apply.
3. Does CN1980639 protect specific compounds or all pyrimidine derivatives?
It claims a class of compounds with certain substitutions, not all pyrimidine derivatives, but covers many variants within the defined scope.
4. Are there international equivalents of CN1980639?
No, the patent is specific to China. Similar patents exist in US and Europe but are not direct equivalents.
5. What are the key factors to watch regarding patent landscape?
Overlap with international patents, scope breadth, expiry dates, and jurisdictional differences inform freedom-to-operate analysis.
References
- State Intellectual Property Office of China (SIPO). (2011). Patent CN1980639.
- U.S. Patent and Trademark Office (USPTO). (2004). US7572753.
- European Patent Office (EPO). (2010). EP1523234.
- World Intellectual Property Organization (WIPO). (2010). WO2010051223.
